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Similar familial risk in multiple sclerosis subgroups 
Introduction 
Multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system (CNS), 
shows great variation in clinical course and severity. This has led to attempts to identify sub-
phenotypes potentially representing independent diseases. One of the hallmarks of MS is the 
presence of so called oligoclonal bands (OCBs) in the cerebrospinal fluid (CSF). OCBs appear on 
electrophoretic or isoelectric separation of CSF proteins and consist of clones of 
immunoglobulin G (IgG) produced by CNS resident plasma cells and plasma blasts1. The 
presence of OCB in CSF indicates intrathecal activity of B-cell believed to contribute to the 
CNS inflammation,2 and thus, the bands are relevant as a diagnostic biomarker in MS.  
However, a subset of patients diagnosed with MS present with no evidence of OCB in the CSF 
(i.e., OCB negative (OCB-)). The proportion varies across the world with the lowest figures in 
Scandinavia (5-10%) and the highest numbers in Asia (50-97%).3,4 In addition, although OCB 
positive (OCB+) and OCB- MS share basic clinical characteristics, OCB- patients have been 
reported to differ significantly also for the other para-clinical tool in MS diagnostics, the MS-
typical lesions seen on magnetic resonance imaging (MRI). OCB- MS patients have less white 
matter lesions and less atrophy in the regional gray matter, basal ganglia and diencephalon5, and 
also differ in the MRI T2 lesion distribution pattern6. Different clinical and epidemiological 
characteristics have also been reported7. Maybe more importantly, the strongest genetic 
association in OCB- MS is not the classical MS risk allele human leukocyte antigen (HLA) 
DRB1*15:01, but HLA DRB1*04:043. Subsequently, whole genome association studies of 
OCB- patients have revealed partly different genetic associations compared to OCB+ MS8. 
Altogether, MRI lesion distribution and HLA associations may well be interpreted to indicate 
that the two MS subtypes have different immune specificities and thus may differ in critically 
important disease mechanisms. 
Materials and methods 
In a previous study, we reported familial risks for MS patients using nationwide registers from 
Sweden9. By linking these data to the Swedish MS registry (SMSreg; http://www.neuroreg.se), we 
were able to find information on OCB status. To be consistent with the majority who only had 
one lumbar puncture and to eliminate possible bias due to effect of treatment or physician 
knowledge, we used the recorded OCB status from the first assessment. Details regarding the 
registers and patient identification are available in the online supplementary material.  
To explore the etiology between OCB- MS and MS, we divided our MS population into four 
groups based on OCB and MS status (Supplementary Table 2) and estimated the risk for a 
relative to a patient diagnosed with OCB- MS to be diagnosed with MS. By defining a person 
diagnosed with OCB-MS as not having MS, we were able to artificially adjust for OCB- MS 
and to estimate to what extent common causes for OBC- MS and MS exist. Our method is 
described and motivated in full in the supplementary methods. Further, to investigate the 
difference in MS risk in OCB- and OCB+ individuals, we applied the same analysis to OCB+ 
individuals.  
Familial risks were measured by odds ratios (ORs) using logistic regression. A robust sandwich estimator 
of standard errors was used to account for non-independence due to familial clustering.   
Results 
In the Swedish MS registry, we were able to identify 4,569 MS patients with known OCB 
status. Among these patients, 525 had ever tested negative for OCB and 37 of these obtained 
OCB+ results at a later time point(s). Excluding these resulted in a total of 488 OCB- patients. 
Demographic information is presented in Supplementary Table 1.  
Results of familial risks of MS in relatives of patients with OCB+/OCB− status are shown in 
Table 1. Significant risks for developing MS were observed among several different 
relationships, such as parents, offspring, and siblings, to OCB- MS patients. The ORs for 
combined first-degree relatives and second-degree relatives to an OCB- MS patient were 5.22 
(95% confidence interval (CI): 3.47-7.87) and 2.59 (95%CI: 1.50-4.45), respectively. The 
corresponding estimates for the relatives to the OCB+ individuals were similar (6.23 (95% CI: 
5.43-7.14) for first-degree relatives and 2.33 (95% CI: 1.87-2.90) for second-degree relatives).  
Discussion 
Our findings showed that despite the diverging genetic and imaging associations, a common 
genetic background seems to be at play in both OCB+ and OCB- MS. To investigate if the 
association could be due to a common autoimmune genetic background, the familial risks for 
two autoimmune conditions, rheumatoid arthritis (RA) and type 1 diabetes (T1D), were 
investigated among relatives to MS patients with different OCB status.10 The risks for first-
degree relatives to OCB- patients to develop RA or T1D were nonsignificant (Supplementary 
Table 3 and 4), arguing that the familial risk of MS in OCB- MS is unlikely due to a common 
autoimmune genetic background. Interestingly, a small but increased risk for RA was found in 
relatives to individuals with OCB+ MS, and amongst all MS patients. The lack of risk in the 
OCB- group might be due to low numbers, but as the majority of the patients in our sample 
were OCB+, our unexpected finding is interesting and opens up for further speculations about 
joint mechanisms in MS and RA. In comparison, though, risks of RA were much smaller than 
the risks of MS. The risk of T1D was, on the other hand, not significant; however, this was still 
in line with the systematic review by Dobson and Giovannoni10 as the registry based studies 
included in their article showed no familial association with T1D. 
One may argue that our sample size of only 488 OCB- MS patients is a limitation of the study. 
However, the main objective of our study was to investigate whether the underlying genetic 
backgrounds differ by estimating the familial risks. With such a modest number of individuals, 
had there been no or very small risks we may not have had sufficient power to detect the risks. 
The estimates in our study were not only significant but also comparable to our previously 
published estimates of MS familial risks9 based on the total Swedish MS population, of which 
90% can be assumed to be OCB+.3 Therefore, we conclude that although the main HLA 
association differs between OCB+ and OCB- MS, the genetic background for the two groups is 
indeed shared. In addition to arguing for homogeneity of the MS entity, our findings support 
OCB- MS to be a relatively homogeneous group itself; as had there been a significant 
“contamination” of MS-mimicking conditions in the OCB- group the familial risk would have 
been affected negatively.  
Furthermore, the influence of course type on our results can be speculated upon. Due to the 
anonymization during the linkage process, it is not possible for us to test this, but looking at 
unlinked data revealed that close to 90% of both the OCB+ and OCB- patients group had a 
relapsing remitting onset, numbers that are very unlikely to influence the results of our study. 
In summary, we found similar familial risks for these two subgroups of MS, arguing against the 
heterogeneity between OCB- subtype and “standard” OCB+ MS. Our study shows how familial 
risks, obtained from population-based data, can have a bearing on problems of taxonomy 
originating from biomarker studies. 
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Table 1. Odds ratios of MS in relatives of patients with OCB- and OCB+ MS a 
Relationship to proband 
Relatives to OCB- patients  
(N, %) 
 















First  degree relative 2291 (23, 1.0%) 
18486 (218, 
1.2%) 
45 706 065 (87451, 0.2%) 5.22 (3.47-7.87) <0.0001 6.23 (5.43-7.14) <0.001 
Parent 847 (11, 1.3%) 7314(106, 1.4%) 16 624 232 (36036, 0.2%) 
6.06 (3.34-
10.98) 
<0.0001 6.77 (5.57-8.23) <0.001 
Offspring 789 (2, 0.3%) 5940(25, 0.4%) 16 618 688 (29150, 0.2%) 1.45 (0.36-5.76) 0.60 2.41 (1.60-3.61) <0.001 







Second degree relative 2978 (13, 0.4%) 24162 (79, 0.3%) 67 773 585 (114423, 0.2%) 2.59 (1.50-4.45) 0.001 2.33 (1.87-2.90)d <0.001 
Grandparent 643 (1, 0.2%) 6428(20, 0.3%) 17 3485 87 (39421, 0.2%) 0.68 (0.10-4.86) 0.70 1.37 (0.87-2.17) 0.18 
Grandchild 396 (1, 0.3%) 2820(1, 0.0%) 17 329 180 (16178, 0.1%) 
2.71 (0.41-
18.06) 
0.30 0.38 (0.05-2.69) 0.33 
Uncle/aunt 553 (8, 1.4%) 5400(41, 0.8%) 14 791 484 (40112, 0.3%) 
5.40 (2.70-
10.79) 
<0.0001 2.81 (2.05-3.87) <0.001 
Nephew/niece 1159 (1, 0.1%) 7991(11, 0.1%) 14 761 996 (13858, 0.1%) 0.92 (0.13-6.54) 0.93 1.47 (0.82-2.64) 0.20 
Paternal half-sibling 144 (1, 0.7%) 919(5, 0.5%) 2 009 079 (2772, 0.1%) 
5.06 (0.70-
36.59) 
0.11 3.96 (1.66-9.44) 0.002 
Maternal half-sibling 83 (1, 1.2%) 604(1, 0.2%) 1 533 259 (2082, 0.1%) 
8.97 (1.23-
65.39) 
0.03 1.22 (0.17-8.68) 0.84 
Abbreviations: MS: multiple sclerosis; OCB, oligoclonal band; OCB-, oligoclonal band negative; OCB+, oligoclonal band positive; OR, odds ratio; CI, confidence intervals 
a Affected are the number of relatives diagnosed with MS. Relatives to controls are those relatives to individuals not diagnosed with MS (including OCB-, OCB+ or MS without 
OCB status).  
OR OCB-: the odds of MS in relatives to OCB- patients compared to the odds of MS in relatives to controls; 
OR OCB+: the odds of MS in relatives to OCB+ patients compared to the odds of MS in relatives to controls. 
b A robust (sandwich) estimator of standard errors was used to account for non-independence due to familial clustering. For combined first degree and second degree relatives, 
the non-independence cannot be fully adjusted, however the 95% CI are assumed not to vary much due to the substantial sample size 
c Bonferroni correction was applied to adjust for multiple testing (N = 11, significant level set as P < 0.005) 
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Similarly,	we	also	estimated	the	ORs	of	being	diagnosed	with	MS	in	individuals	who	had	relatives	
with	OCB+	MS	(group	2)	compared	with	those	who	did	not	have	relatives	diagnosed	with	MS	(group	
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Number	of	patients	 488	 4	081	 8	739	 27	078	 28	161	
Mean	age	at	onset,	years	(SD)b	 34.8	(10.1)	 33.2	(10.6)	 33.8	(11.0)	 47.3	(15.2)	 43.8	
Mean	calendar	year	of	birth	 1960	 1962	 1958	 1946	 1947	
Mean	calendar	year	at	onset	 1995	 1995	 1993	 1994	 1991	
Mean	calendar	year	at	CSF	date	 2000	 2000	 2002	 NA	 NA	


























Adjusted	OR	(95%CI)	 P-valued	 RR	(95%	CI)	 P-valued	
OCB-	 2291(16,	0.7)	 45	706	065	(311	278,	0.7)	 0.9(0.55-1.48)	 0.68	 0.81	(0.48-1.37)	 0.44	
OCB+	 18	486	(179,	1.0)	 45	706	065	(311	278,	0.7)	 1.3(1.12-1.50)	 0.0006	 1.31(1.12-1.53)	 0.001	
OCB	(OCB+	and	OCB-)	 20	777	(195,	0.9)	 45	706	065	(311	278,	0.7)	 1.25(1.09-1.44)	 0.002	 1.18(1.02-1.37)	 0.03	














Adjusted	OR	(95%CI)	 P-valued	 RR	(95%	CI)	 P-valued	
OCB-	 2291(41,	1.0)	 45	706	065	(678	287,	1.5)	 0.93	(0.68-1.26)	 0.63	 0.95	(0.68-1.32)	 0.75	
OCB+	 18	486	(306,	1.7)	 45	706	065	(678	287,	1.5)	 0.90	(0.80-1.01)	 0.08	 0.88	(0.78-1.00)	 0.04	
OCB	(OCB+	and	OCB-)	 20	777	(347,	1.7)	 45	706	065	(678	287,	1.5)	 0.91	(0.81-1.01)	 0.07	 0.89	(0.79-1.01)	 0.08	



































































									U1	 	 						C	 	 	U2	
	 						MS1	 	 	MS2	
	 	 					UMS	
Supplementary	Figure	2.	Directed	Acyclic	Graph	to	illustrate	if	familial	factors	exist	that	
contributes	to	OCB-	and	MS.	Abbreviations:	OCB-	oligoclonal	band	negative;	MS	–	multiple	
sclerosis;		
	
	
	
 
 
 
 
 
 
